Intravenous Vitamin C in Cancer
A brief overview of its use and considerations
By Michael Traub, ND, DHANP, FABNO, and Paul S. Anderson, ND
About the Authors
Michael Traub ND, DHANP, FABNO, has been practicing in Hawaii since 1985. He is past-president of the American Association of Naturopathic Physicians (AANP) and received the AANP’s Naturopathic Physician of the Year award in 2006. He is the author of Essentials of Dermatological Diagnosis and Integrative Therapeutics. His website is www.michaeltraubnd.com.
Paul S. Anderson, ND, is medical director of Anderson Medical Specialty Associates, Seattle, Washington. He was formerly a professor of pharmacology and clinical medicine at Bastyr University, Kenmore, Washington, and chief of IV services for Bastyr Oncology Research Center. Anderson graduated from the National College of Natural Medicine, Portland, Oregon, and began instructing classes at naturopathic medical schools in the early 1990s. He continues to hold board review classes and continuing medical education courses for most of the naturopathic programs in the United States and Canada. He also is a founding board member of the Academy of Parenteral Therapies specialty group and an instructor and author for the International IV Nutritional Therapy for Professionals IV Therapy training group.
Low-dose Intravenous Vitamin C
Balancing Blood Chemistry
Table 1. BIORC Formula for an Infusion of 25 g of Intravenous Vitamin C
|Vitamin C||500 mg/mL||50 mL|
|Calcium chloride||100 mg/mL||1 mL|
|Magnesium chloride||200 mg/mL||2 mL|
|Potassium chloride||2 mEq||1 mL|
|Sterile water||500 mL|
For a total volume of 554 mL and an osmolarity of 558 mOsm/L.
Table 2. BIORC Formula for an Infusion of 50 g of Intravenous Vitamin C
|C-500||500 mg/mL||100 mL|
|Calcium chloride||100 mg/mL||3 mL|
|Potassium chloride||2 mEq||4 mL|
|Magnesium chloride||200 mg/mL||5 mL|
|Sterile water||500 mL|
For a total volume of 612 mL and an osmolarity of 1001 mOsm/L.
Separation of B Vitamins and Glutathione From the Oxidative IVC Therapy
Considerations of IVC Usage
Contraindications to IVC
Appendix 2. A “safe” recommendation for G6PD testing.22 Run G6PD/ hemoglobinopathy screening on any person getting any single IVC over 10-15 g.
- Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011;2(2):78-88.
- Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses. 1995;44(3):207-213.
- Stephenson C. Study of high-dose intravenous (IV) vitamin C treatment in patients with solid tumors. Clinical Trials. http://clinicaltrials.gov/ct2/show/NCT00441207. Accessed January 24, 2014.
- Copenhagen University Hospital at Herlev. Vitamin C as an anti-cancer drug. Clinical Trials. http://clinicaltrials.gov/ct2/show/NCT01080352. Accessed January 24, 2014.
- Thomas Jefferson University. Pilot trial of intravenous vitamin C in refractory non-Hodgkin lymphoma (NHL). Clinical Trials. http://clinicaltrials.gov/ct2/show/NCT00626444. Accessed January 24, 2014.
- Situs Cancer Research Center. Study of high dose intravenous (IV) ascorbic acid in measurable solid tumor disease. Clinical Trials. http://clinicaltrials.gov/ct2/show/NCT01125449. Accessed January 24, 2014.
- Hoffer J. Trial of chemotherapy plus intravenous vitamin C in patients with advanced cancer for whom chemotherapy alone is only marginally effective. Clinical Trials. http://clinicaltrials.gov/ct2/show/NCT01050621. Accessed January 24, 2014.
- Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005;102(38):13604-13609.
- Ichim TE, Minev B, Braciak T, et al. Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med. 2011;9:25.
- Chen P, Stone J, Sullivan G, Drisko JA, Chen Q. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med. 2011;51(3):681-687.
- Lamson DW, Gu YH, Plaza SM, Brignall MS, Brinton CA, Sadlon AE. The vitamin C:vitamin K3 system- enhancers and inhibitors of the anticancer effect. Altern Med Rev. 2010;15(4):345-351.
- Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007;104(21):8749-8754.
- Ochi M, Lamson D. The concern about B-vitamins affecting the oxidant effect of intravenous ascorbate for malignancy. Altern Med Rev. 2011;16(Supp):1S-5S.
- Chen P, Stone J, Sullivan G, Drisko JA, Chen Q. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med. 2011 May 30.
- Nelson DL, Lehninger AL, Cox MM. Lehninger Principles of Biochemistry. Macmillan; 2008.
- Cunningham JJ. The glucose/insulin system and vitamin C: implications in insulin-dependent diabetes mellitus. J Am Coll Nutr. 1998;17(2):105-108.
- Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE. 2010;5(7):e11414.
- Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med. 1985;145(5):950-951.
- Wong K, Thomson C, Bailey RR, Mcdiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med. 1994;24(4):410-411.
- Mcallister CJ, Scowden EB, Dewberry FL, Richman A. Renal failure secondary to massive infusion of vitamin C. JAMA. 1984;252(13):1684.
- Anderson P. Intravenous vitamin C in naturopathic oncology. Paper presented at: Oncology Association of Naturopathic Physicians; 2012; Scottsdale, Arizona.
- Hininger I, Waters R, Osman M, et al. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med. 2005;38(12):1565-1570.
- Roussel AM, Hininger-favier I, Waters RS, Osman M, Fernholz K, Anderson RA. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation. Altern Med Rev. 2009;14(1):56-61.
- Mühlhöfer A, Mrosek S, Schlegel B, et al. High-dose intravenous vitamin C is not associated with an increase of pro-oxidative biomarkers. Eur J Clin Nutr. 2004;58(8):1151-1158.